医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Global and China Insulin Market Reviewed in New In-Demand Transparency Market Research Report Now Available at MarketPublishers.com

2012年10月10日 PM08:06
このエントリーをはてなブックマークに追加


 

LONDON

Diabetes has become a common problem for almost 400 million people all over the world in 2011. Being mainly treated by insulin, it spurs expansion of the global insulin market. As a result, the latter one surpassed USD 12.4 billion in 2011 and is expected to demonstrate considerable growth of around 11 percent per year in the future. The market for insulin is likely to be around USD 32.3 billion by 2019.

China’s market for insulin was evaluated at USD 724 million 2011. However, it is set to expand significantly within next 5-6 years to amount to USD 3.3 billion by 2019.

New market research report “Insulin Market – Global And China Industry Analysis, Size, Share, Growth, And Forecast 2011 – 2018” worked out by Transparency Market Research offers a deep insight into the global and China market for insulin. In-depth analysis of past and present market trends, detailed examination of product types, market shares overview, data on market revenue and volume, profiles of the key players can be found in the study. The research also includes industry forecast to 2017.

Report Details:

Title: Insulin Market – Global And China Industry Analysis, Size, Share, Growth, And Forecast 2011 – 2018

Published: September, 2012

Pages: 105

Price: US$ 4,395.00

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/insulin_market_global_n_china_industry_analysis_size_share_growth_n_forecast_2011_2018.html

More Medicine, Pharmaceuticals and Biotechnology Market Research Reports by Transparency Market Research Include:

More new market research reports by Transparency Market Research can be found at http://marketpublishers.com/members/transparency/info.html

CONTACT

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax:
+44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表